Immune Regulation| PD Dr. Petra Hoffmann / Prof. Dr. Matthias Edinger

Management

	PD Dr. Petra Hoffmann Phone: +49 941-944 38492 E-Mail: Petra.Hoffmann@ukr.de
	Prof. Dr. Matthias Edinger Phone: +49 941-944 5580 E-Mail: Matthias.Edinger@ukr.de

Secretariat

Karin Meissner
Phone: +49 941-944 5582
E-Mail: Karin.Meissner@ukr.de

• Minderjahn J, Schmidt A,  Fuchs A,  Schill R, Raithel J, Babina M, Schmidl C, Gebhard C, Schmidhofer S, Mendes K, Ratermann A, Glatz D, Nützel M, Edinger M, Hoffmann P, Spang R, Langst G, Imhof A, Rehli M. 2020. Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1. Nat Comm 11(1):402. doi: 10.1038/s41467-019-13960-2.
• Delacher M, Imbusch CD, Hotz-Wagenblatt A, Mallm J-P, Bauer K, Simon M, Riegel D, Rendeiro AF, Bittner S, Sanderink L, Pant A, Schmidleithner L, Braband KL, Echtenachter B, Fischer A, Giunchiglia  V, Hoffmann P, Edinger M, Bock C, Rehli M, Brors B, Schmidl C and  Feuerer M. 2020. Identification of nonlymphoid-tissue regulatory T cell precursors. Immunity 52(2):295-312.e11. doi: 10.1016/j.immuni.2019.12.002.
• Riegel C, Boeld TJ, Doser K, Huber E, Hoffmann P, Edinger M. 2019. Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. Leukemia. Nov 12. doi: 10.1038/s41375-019-0625-3. [Epub ahead of print]
• Klobuch S, Weber D, Holler B, Edinger M, Herr W, Holler E, Wolff D. 2019. Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease - single center experience. Ann Hematol. 98(10):2399-2405. doi: 10.1007/s00277-019-03768-x.
• Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, Hoffmann P, Aslanidis C, Lang P, Holler E, Eggert A, Corbacioglu S. 2019. Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplant. 54(11):1859-1867. doi: 10.1038/s41409-019-0550-0.
• Cossarizza A, … Hoffmann P,…Edinger M et al. 2019. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol. 49(10):1457-1973. doi: 10.1002/eji.201970107.
• Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M. 2019. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica 104(5):955-962. doi: 10.3324/haematol.2018.206797.
• Hoffmeister H, Fuchs A, Strobl L, Sprenger F, Gröbner-Ferreira R, Michaelis S, Hoffmann P, Nazet J, Merkl R, Längst G. 2019. Elucidation of the functional roles of the Q and I motifs in the human chromatin-remodeling enzyme BRG1. J Biol Chem. 294(9):3294-3310. doi: 10.1074/jbc.RA118.005685.
• Edinger M, Hoffmann P. Thymus-derived CD4+CD25+ FOXP3+ regulatory T cells in GVHD. 2018. In: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. 2nd Edition. Models in Discovery and Translation. Editors: Gerard Socie, Robert Zeiser, Bruce R. Blazar. Academic Press. Published Date: 6th December 2018
• Doebbeler M, Koenig C, Krzyzak L, Seitz C, Wild A, Ulas T, Baßler K, Kopelyanskiy D, Butterhof A, Kuhnt C, Kreiser S, Stich L, Zinser E, Knippertz I, Wirtz S, Riegel C, Hoffmann P, Edinger M, Nitschke L, Winkler T, Schultze JL, Steinkasserer A, Lechmann M. 2018. CD83 expression is essential for Treg cell differentiation and stability. JCI Insight 3(11). pii: 99712. doi: 10.1172/jci.insight.99712.
• Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, Hakim F, Malard F, Jagasia M, Lawitschka A, Hansen JA, Pulanic D, Holler E, Dickinson A, Weissinger E, Edinger M, Sarantopoulos S, Schultz KR. 2018. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplant. 2018 Jul; 53(7):832-837. doi: 10.1038/s41409-018-0092-x.
• Noguchi S,…Edinger M, … Forrest ARR, Hayashizaki Y. 2017. FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112. doi: 10.1038/sdata.2017.112.
• Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. 2017. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31(11): 2398-2406. doi: 10.1038/leu.2017.253.
• Bohmann EM, Fehn U, Holler B, Weber D, Holler E, Herr W, Hoffmann P, Edinger M, Wolff D. 2017. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset. Ann Hematol. 96(2):299-310. doi: 10.1007/s00277-016-2881-x.
• Ullrich E, Salzmann-Manrique E, Bakhtiar S, Bremm M, Gerstner S, Herrmann E, Bader P, Hoffmann P, Holler E, Edinger M and Wolff D. 2016. Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. Front. Immunol. 7:595.
• Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. 2016. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 24(5):657-671.
• Haarer J, Riquelme P, Hoffmann P, Schnitzbauer A, Schlitt HJ, Sawitzki B, Geissler EK, Hutchinson JA. 2016. Early Enrichment and Restitution of the Peripheral Blood Treg Pool Is Associated With Rejection-Free Stable Immunosuppression After Liver Transplantation. Transplantation 100(7):e39-40.
• Edinger M. 2016. Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation., J Clin Invest. 126(4):1248-50. doi: 10.1172/JCI86827.
• Echtenacher B, Wege AK, Schardt K, Bitterer F, Gehmert S, Hoffmann P, Stroszczynski C, Jung EM. 2016. High-Resolution Ultrasound Including Contrast-Enhanced Ultrasound (CEUS) for the Detection of Gas Formation during Aspergillus Fumigatus Infection in Mice. Ultraschall Med. 37(3):277-82. doi: 10.1055/s-0034-1398873.
• Renner K, Geiselhöringer AL, Fante M, Bruss C, Färber S, Schönhammer G, Peter K, Singer K, Andreesen R, Hoffmann P, Oefner P, Herr W, Kreutz M. 2015. Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions. Eur J Immunol. 45(9):2504-16.
• Edinger M. 2015. Regulatorische T-Zellen. In: Hämatopoetische Stammzellen, editors: Herr/Theobald/Ehninger/Einsele/Meyer. Deutscher Ärzte-Verlag Köln, ISBN 978-3-7691-0584-1.
• Thomas S, Klobuch S, Podlech J, Plachter B, Hoffmann P, Renzaho A, Theobald M, Reddehase MJ, Herr W, Lemmermann NA. 2015. Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice. PLoS Pathog. 11(7):e1005049.
• Hautmann AH, Wolff D, Hilgendorf I, Fehn U, Edinger M, Hoffmann P, Herr W, Kölbl O, Holler B, Sporrer D, Holler E, Hautmann MG. 2015. Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. Radiother Oncol. 116(2):287-93.
• Hermann FJ, Rodriguez Gomez M, Doser K, Edinger M, Hoffmann P, Schiechl G, Talke Y, Göbel N, Schmidbauer K, Syed SN, Brühl H, Mack M. 2015. Basophils inhibit proliferation of CD4⁺ T cells in autologous and allogeneic mixed lymphocyte reactions and limit disease activity in a murine model of graft versus host disease. Immunology 145(2):202-12.
• Meinhardt K, Kroeger I, Bauer R, Ganss F, Ovsiy I, Rothamer J, Büttner M, Atreya I, Waldner M, Bittrich M, Lehmann CH, Rieger MA, Beilhack A, Zeiser R, Edinger M, Dudziak D, Mackensen A, Rehli M, Ullrich E. 2015. Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncoimmunology 4(1):e981483. eCollection 2015 Jan.
• Zimara N, Florian C, Schmid M, Malissen B, Kissenpfennig A, Männel DN, Edinger M, Hutchinson JA, Hoffmann P, Ritter U. 2014. Langerhans cells promote early germinal center formation in response to Leishmania-derived cutaneous antigens. Eur J Immunol. 44(10):2955-67.
• Schmid PM, Bouazzaoui A, Doser K, Schmid K, Hoffmann P, Schroeder JA, Riegger GA, Holler E, Endemann DH. 2014. Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease. Biol Blood Marrow Transplant. 1493-500.
• Schmidl C, Renner K, Peter K, Eder R, Lassmann T, Balwierz PJ, Itoh M, Nagao-Sato S, Kawaji H, Carninci P, Suzuki H, Hayashizaki Y, Andreesen R, Hume DA, Hoffmann P, Forrest AR, Kreutz MP, Edinger M, Rehli M; FANTOM consortium. 2014. Transcription and enhancer profiling in human monocyte subsets. Blood. 123(17):e90-9.
• Schmidl C, Hansmann L, Lassmann T, Balwierz PJ, Kawaji H, Itoh M, Kawai J, Nagao-Sato S, Suzuki H, Andreesen R, Hayashizaki Y, Forrest AR, Carninci P, Hoffmann P, Edinger M, Rehli M; FANTOM consortium. 2014. The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood 123(17):e68-78.
• Grube M, Loeffler J, Mezger M, Krüger B, Echtenacher B, Hoffmann P, Edinger M, Einsele H, Andreesen R, Holler E. 2013. TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. Med Mycol. 51(8):818-25.
• Hilgendorf I, Mueller-Hilke B, Kundt G, Holler E, Hoffmann P, Edinger M, Freund M, Wolff D. 2012. The lack of memory B cells including T cell independent IgM+ IgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. Transpl Int. 25(1):87-96.
• Ullrich E, Bosch J, Aigner M, Voelkl S, Kroeger I, Hoffmann P, Kreutz M, Dudziak D, Gerbitz A. 2012. Advances in cellular therapy: 6th international symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany. Cancer Immunol Immunother. 61(3):433-43.
• Hansmann L, Schmidl C, Kett J, Steger L, Andreesen R, Hoffmann P, Rehli M, Edinger M. 2012. Dominant Th2 Differentiation of Human Regulatory T Cells upon Loss of FOXP3 Expression. J Immunol. 188(3):1275-82.
• Kreutz M, Karrer S, Hoffmann P, Gottfried E, Szeimies R-M, Hahn J, Edinger M, Landthaler MI, Andreesen R, Merad M and Holler E. 2012. Whole-Body UVB Irradiation during Allogeneic Hematopoietic Cell Transplantation Is Safe and Decreases Acute Graft-versus-Host Disease. J Invest Dermatol. 132(1):179-87.
• Hoetzenecker W, Echtenacher B, Guenova E, Hoetzenecker K, Woelbing F, Brück J, Teske A, Valtcheva N, Fuchs K, Kneilling M, Park JH, Kim KH, Kim KW, Hoffmann P, Krenn C, Hai T, Ghoreschi K, Biedermann T, Röcken M. 2011. ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat Med. 18(1):128-34.
• Heesemann L, Kotz A, Echtenacher B, Broniszewska M, Routier F, Hoffmann P, Ebel F. 2011. Studies on galactofuranose-containing glycostructures of the pathogenic mold Aspergillus fumigatus. Int J Med Microbiol. 301(6):523-30.
• Edinger M, Hoffmann P. 2011. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol.. 23(5):679-84.
• Schmidl C, Hansmann L, Andreesen R, Edinger M, Hoffmann P, Rehli M. 2011. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg cells. Eur J Immunol., 41(5):1491-1498.
• Hoffmann P, Eder R, Edinger M. 2011. Polyclonal expansion of human CD4(+) CD25(+) regulatory T cells. Methods Mol Biol. 677:15-30.
• Dirr F, Echtenacher B, Heesemann J, Hoffmann P, Ebel F, Wagener J. 2010. AfMkk2 is required for cell wall integrity signaling, adhesion, and full virulence of the human pathogen Aspergillus fumigatus. Int J Med Microbiol. 300(7):496-502.
• Hansmann L, Schmidl C, Boeld TJ, Andreesen R, Hoffmann P, Rehli M, Edinger M. 2010. Isolation of intact genomic DNA from FOXP3-sorted human regulatory T cells for epigenetic analyses. Eur J Immunol. 40(5):1510-2.
• Landfried K, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D, Hilgendorf I, Hahn J, Edinger M, Hoffmann P, Obermeier F, Schoelmerich J, Andreesen R, Holler E. 2010. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clin Exp Immunol. 159(1):87-92.
• Hofmann C, Dunger N, Grunwald N, Hämmerling GJ, Hoffmann P, Schölmerich J, Falk W, Obermeier F. 2010. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut 59(10):1347-54.
• Kotz A, Wagener J, Engel J, Routier F, Echtenacher B, Pich A, Rohde M, Hoffmann P, Heesemann J, Ebel F. 2010. The mitA gene of Aspergillus fumigatus is required for mannosylation of inositol-phosphorylceramide, but is dispensable for pathogenicity. Fungal Genet Biol. 47(2):169-78.
• Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, Rehli M. 2009. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res. 19:1165-74.
• Fowler D, Hoffmann P, Edinger M. 2009. Functionally defined T cell subsets in transplantation biology and therapy: regulatory T cells and Th2 cells. Cancer Treat Res. 144:155-86.
• Wang X, Haniffa MA, Holtick U, Collin MP, Jackson G, Hilkens CMU, Holler E, Edinger M, Hoffmann P, Dickinson AM. 2009. Natural regulatory T cell suppression of human CD8+ T cell mediated graft-versus-host reaction requires their presence during priming. Transplantation 88:188-97.
• Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, Olek S, Dietmaier M, Andreesen R, and Edinger M. 2009. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 39:1088-97.
• Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, Türbachova I, Hamann A, Olek S, and Huehn J. 2007. DNA demethylation in the human FOXP3 locus discriminates Tregs from activated FOXP3+ conventional T cells. Eur J Immunol. 37:2378-89.
• Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, and Kreutz M. 2007. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812-9.
• Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, and Edinger M. 2006. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T cell lines upon in vitro expansion. Blood 108:4260-7.
• Hoffmann P, Boeld TJ, Eder R, Piseshka B, Albrecht J, Doser K, Dada A, Niemand C, Assenmacher M, Orso E, Andreesen R, Holler E, Edinger M. 2006. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 12:267-274.
• Hoffmann P, Edinger M. 2006. CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol. 43:62-9.
• Hoffmann P, Boeld TJ, Piseshka B, Edinger M. 2005. Immunomodulation after allogeneic bone marrow transplantation by CD4+CD25+ regulatory T cells. Microbes Infect. 7:1066-1072
• Hoffmann P, Ermann J, Edinger M. 2005. CD4+CD25+ regulatory T cells in allogeneic stem cell transplantation. Curr. Topics Microbiol. & Immunol. 293:265-285.
• Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, Negrin RS, Fathman CG, Strober S. 2005. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 105:2220-6.
• Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karimi M, Cao YA, Marina N, Contag CH, Negrin RS. 2005. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res. 11(12):4561-70.
• Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA, Charo I, Cook DN, Weissman IL, Strober S, and Engleman EG. 2004. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat.Med. 10:510-517
• Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, and Edinger M. 2004. Large Scale In Vitro Expansion of Polyclonal Human CD4+CD25high Regulatory T Cells. Blood 104:895-903
• Zeng D, Lan F, Hoffmann P, and Strober S. 2004. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation 77:S9-S11.
• Mandl SJ, Mari C, Edinger M, Negrin RS, Tait JF, Contag CH, Blankenberg FG. 2004. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 3(1):1-8.
• Edinger M, Hoffmann P, ErmannJ, Drago K, Fathman CG, Strober S, and Negrin RS. 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat.Med. 9:1144-1150.
• Edinger M, Hoffmann P, Contag CH, and Negrin RS. 2003. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 31:172-179.
• Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. 2003. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101(2):640-8.
• Hoffmann P, Ermann J, Edinger M, Fathman CG, and Strober S. 2002. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J.Exp.Med. 196:389-399.
• Millan MT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC, Tan JC, Salvatierra O, Hoppe RT, and Strober S. 2002. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73:1386-1391.
• Zeng D, Hoffmann P, Lan F, Huie P, Higgins J, and Strober S. 2002. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood 99:1449-1457.
• Negrin RS, Edinger M, Verneris M, Cao YA, Bachmann M, Contag CH. 2002. Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. Ann Hematol. 81 Suppl 2:S44-5.
• Mandl S, Schimmelpfennig C, Edinger M, Negrin RS, Contag CH. 2002. Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem Suppl. 39:239-48.
• Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, Contag CH. 2002. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 38(16):2128-36.
• Hardy J, Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH. 2001. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol. 29(12):1353-60.
• Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH.1999. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1(4):303-10.